Tag Archives: regorafenib

FDA Approves Regorafenib for Metastatic CRC

  The FDA today approved the use of the drug regorafenib (brand name Stivarga) for patients whose metastatic colorectal cancer has progressed despite all currently approved treatment regimens. This is the second new drug approved by the FDA recently after a drought of 5 years in approving new treatments for metastatic colorectal cancer (mCRC). Regorafenib was placed into the  FDA’s “fast-track” approval process after the international, multicenter Phase III CORRECT trial  showed improved survival (from 5 to 6.4 months) in all mCRC patients, including those having both non-mutated and mutated KRAS types.

Regorafenib Now Available Via Expanded Access

Click Here to Get updates from Fight Colorectal Cancer The first four sites where colorectal cancer patients can get regorafenib are now open.  Bayer Healthcare expects to open additional sites in the next two or three weeks. Colorectal cancer patients whose cancer has gotten worse on all standard treatments can now be considered for the Regorafenib Extended Access program. Bayer Healthcare has applied for FDA approval of regorafenib to treat colorectal cancer, but until it is actually approved and on the market, the expanded access program is the only way patients who might benefit can receive it. Last fall, early results from the randomized Phase 3 CORRECT clinical trial showed

“Report from 2012 GI Cancers Symposium” Available for Viewing

Fight Colorectal Cancer has posted a recording of its February webinar, Report from the 2012 GI Cancers Symposium, held in partnership with the Colon Cancer Alliance. Each year, the best and brightest minds in gastrointestinal oncology meet to discuss the latest research into colorectal, pancreatic, esophageal and other GI cancers. The 2012 symposium offered major news for people living with colorectal cancer, and we were proud to be able to bring that information to you. Listen in as Dr. Dan Sargent of the Mayo Clinic Cancer Center and Kim Ryan, Fight Colorectal Cancer’s Director of Patient Information Services, discuss what is on the horizon for patients living with colorectal cancer.

Top